Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri-Menopausal MASLD - PubMed
4 hours ago
- #Cardiometabolic Outcomes
- #Hormone Replacement Therapy
- #MASLD
- Hormone Replacement Therapy (HRT) in peri-menopausal women with MASLD is associated with reduced risks of major adverse liver outcomes (MALO), including ascites, spontaneous bacterial peritonitis (SBP), and liver cirrhosis.
- HRT also lowers the risk of cardiometabolic outcomes such as type 2 diabetes (T2D) and major adverse cardiovascular events (MACE), without increasing the risk of breast cancer or venous thromboembolism (VTE).
- The study found that estrogen-based HRT offers greater benefits compared to progesterone, with more significant risk reductions observed in patients with mild-moderate obesity.
- The research supports the potential benefits of HRT in peri-menopausal women with MASLD, suggesting a need for further clinical trials to confirm these findings.